These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

785 related articles for article (PubMed ID: 25956510)

  • 1. Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.
    Hilhorst M; van Paassen P; Tervaert JW;
    J Am Soc Nephrol; 2015 Oct; 26(10):2314-27. PubMed ID: 25956510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
    Kim SM; Choi SY; Kim SY; Kim J
    Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis.
    Mohammad AJ; Segelmark M
    J Rheumatol; 2014 Jul; 41(7):1366-73. PubMed ID: 24882836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-DPB1 as a Risk Factor for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Cohort Study.
    Hilhorst M; Arndt F; Joseph Kemna M; Wieczorek S; Donner Y; Wilde B; Thomas Epplen J; van Paassen P; Cohen Tervaert JW
    Arthritis Rheumatol; 2016 Jul; 68(7):1721-30. PubMed ID: 26866715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Murosaki T; Sato T; Akiyama Y; Nagatani K; Minota S
    Mod Rheumatol; 2017 Jan; 27(1):95-101. PubMed ID: 27320904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA.
    Gong Y; Shen C; Meng T; Lin W; Hu X; Tang R; Xiong Q; Ooi JD; Eggenhuizen PJ; Chen J; Zhou YO; Luo H; Xu J; Liu N; Xiao P; Xiao X; Zhong Y
    Clin Exp Med; 2024 Apr; 24(1):66. PubMed ID: 38564029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of different ANCA serotypes on the long-term outcome of ANCA-associated vasculitis patients.
    Qi F; Hao J; Wei W
    Ann Med; 2023; 55(2):2289614. PubMed ID: 38056010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective α1-antitrypsin effects in autoimmune vasculitis are compromised by methionine oxidation.
    Ebert M; Jerke U; Eulenberg-Gustavus C; Kling L; Jenne D; Kirchner M; Mertins P; Bieringer M; Elitok S; Eckardt KU; Schreiber A; Salama AD; Kettritz R
    J Clin Invest; 2022 Dec; 132(23):. PubMed ID: 36125911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HLA region in ANCA-associated vasculitis: characterisation of genetic associations in a Scandinavian patient population.
    Lundtoft C; Knight A; Meadows JRS; Karlsson Å; Rantapää-Dahlqvist S; Berglin E; Palm Ø; Haukeland H; Gunnarsson I; Bruchfeld A; Segelmark M; Ohlsson S; Mohammad AJ; Eriksson P; Söderkvist P; Ronnblom L; Omdal R; Jonsson R; Lindblad-Toh K; Dahlqvist J
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38580345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective Role of HLA-DRB1*13:02 against Microscopic Polyangiitis and MPO-ANCA-Positive Vasculitides in a Japanese Population: A Case-Control Study.
    Kawasaki A; Hasebe N; Hidaka M; Hirano F; Sada KE; Kobayashi S; Yamada H; Furukawa H; Yamagata K; Sumida T; Miyasaka N; Tohma S; Ozaki S; Matsuo S; Hashimoto H; Makino H; Arimura Y; Harigai M; Tsuchiya N
    PLoS One; 2016; 11(5):e0154393. PubMed ID: 27166610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing.
    Rao DA; Wei K; Merola JF; O'Brien WR; Takvorian SU; Dellaripa PF; Schur PH
    J Rheumatol; 2015 May; 42(5):847-52. PubMed ID: 25834211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stratified genetic analysis reveals sex differences in MPO-ANCA-associated vasculitis.
    Ekman D; Sennblad B; Knight A; Karlsson Å; Rantapää-Dahlqvist S; Berglin E; Stegmayr B; Baslund B; Palm Ø; Haukeland H; Gunnarsson I; Bruchfeld A; Segelmark M; Ohlsson S; Mohammad AJ; Svärd A; Pullerits R; Herlitz H; Söderbergh A; Omdal R; Jonsson R; Rönnblom L; Eriksson P; Lindblad-Toh K; Dahlqvist J
    Rheumatology (Oxford); 2023 Sep; 62(9):3213-3218. PubMed ID: 37004177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.
    van Dam LS; Dirikgil E; Bredewold EW; Ray A; Bakker JA; van Kooten C; Rabelink TJ; Teng YKO
    Nephrol Dial Transplant; 2021 Jul; 36(8):1408-1417. PubMed ID: 32601673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-neutrophil cytoplasmic antibodies predate symptom onset of ANCA-associated vasculitis. A case-control study.
    Berglin E; Mohammad AJ; Dahlqvist J; Johansson L; Eriksson C; Sjöwall J; Rantapää-Dahlqvist S
    J Autoimmun; 2021 Feb; 117():102579. PubMed ID: 33340843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between serologic profile (ANCA type) and clinical features of renal involvement in ANCA-associated vasculitides.
    Bulanov NM; Makarov EA; Shchegoleva EM; Zykova AS; Vinogradova ES; Novikov PI; Lysenko Kozlovskaya LV; Moiseev SV
    Ter Arkh; 2018 Jun; 90(6):15-21. PubMed ID: 30701899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
    Ozaki S
    Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Neutrophils in ANCA-Associated Vasculitis: The Pathogenic Role and Diagnostic Utility of Autoantibodies.
    Walulik A; Łysak K; Błaszkiewicz M; Górecki I; Gomułka K
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis.
    Csernok E; Lamprecht P; Gross WL
    Curr Opin Rheumatol; 2010 Jan; 22(1):43-8. PubMed ID: 19770659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of PR3-ANCA associated vasculitis.
    Kallenberg CG
    J Autoimmun; 2008; 30(1-2):29-36. PubMed ID: 18162369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.